CR20210060A - Activadores de la respuesta a proteínas desplegadas - Google Patents

Activadores de la respuesta a proteínas desplegadas

Info

Publication number
CR20210060A
CR20210060A CR20210060A CR20210060A CR20210060A CR 20210060 A CR20210060 A CR 20210060A CR 20210060 A CR20210060 A CR 20210060A CR 20210060 A CR20210060 A CR 20210060A CR 20210060 A CR20210060 A CR 20210060A
Authority
CR
Costa Rica
Prior art keywords
cancer cells
activators
small molecules
resistant
erα
Prior art date
Application number
CR20210060A
Other languages
English (en)
Inventor
Paul J Hergenrother
Matthew W Boudreau
David J Shapiro
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of CR20210060A publication Critical patent/CR20210060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Conjunto de biomoduladores ER¿ de moléculas pequeñas que destruyen las células cancerosas de mama, ovario y endometrio ER¿ positivas resistentes a la terapia. Estas pequeñas moléculas tienen un mayor potencial terapéutico debido a la mayor capacidad para destruir las células de cáncer de 5 mama resistentes a la terapia en comparación con BHPI y otras terapias convencionales (terapias endocrinas, tamoxifeno y fulvestrant/ICI). Los nuevos compuestos no solo inhiben la proliferación de las células cancerosas, sino que también realmente las destruye, lo que evita la reactivación de los tumores años después.</p>
CR20210060A 2018-07-03 2019-07-01 Activadores de la respuesta a proteínas desplegadas CR20210060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693641P 2018-07-03 2018-07-03
PCT/US2019/040058 WO2020009958A1 (en) 2018-07-03 2019-07-01 Activators of the unfolded protein response

Publications (1)

Publication Number Publication Date
CR20210060A true CR20210060A (es) 2021-04-08

Family

ID=69059783

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210060A CR20210060A (es) 2018-07-03 2019-07-01 Activadores de la respuesta a proteínas desplegadas

Country Status (22)

Country Link
US (3) US20210276951A1 (es)
EP (1) EP3817741A4 (es)
JP (1) JP2021529757A (es)
KR (1) KR20210027382A (es)
CN (1) CN112423743A (es)
AU (1) AU2019299221A1 (es)
BR (1) BR112020025591A2 (es)
CA (1) CA3103958A1 (es)
CL (1) CL2020003423A1 (es)
CO (1) CO2020016690A2 (es)
CR (1) CR20210060A (es)
DO (1) DOP2020000256A (es)
EA (1) EA202190146A1 (es)
EC (1) ECSP20084330A (es)
IL (1) IL279429A (es)
JO (1) JOP20200344A1 (es)
MA (1) MA53105A (es)
MX (1) MX2021000043A (es)
PE (1) PE20210662A1 (es)
PH (1) PH12020552223A1 (es)
SG (1) SG11202012902WA (es)
WO (1) WO2020009958A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210276951A1 (en) 2018-07-03 2021-09-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response
WO2021222738A1 (en) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Compounds for estrogen receptor positive cancers
WO2022020605A1 (en) * 2020-07-23 2022-01-27 The Board Of Trustees Of The University Of Illinois Treatment of metastasized estrogen receptor positive breast cancer
WO2022032146A1 (en) * 2020-08-07 2022-02-10 Systems Oncology, Llc Methods for inhibiting growth of era positive cancers
MX2023004480A (es) * 2020-10-23 2023-05-04 Univ Illinois Compuestos anticancerigenos selectivos para canceres er-positivos.
WO2024175114A1 (en) * 2023-02-23 2024-08-29 Shanghai Yuyao Biotech Ltd. Boron containing compounds and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478172A1 (en) 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
AU2005214338B2 (en) * 2004-02-13 2011-11-10 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
WO2005097107A2 (en) * 2004-04-08 2005-10-20 Topotarget A/S Diphenyl - indol-2-on compounds and their use in the treatment of cancer
AR056544A1 (es) 2005-09-29 2007-10-10 Wyeth Corp Derivados fenilaminopropanol y metodos de uso de los mismos
US20080146645A1 (en) 2006-08-24 2008-06-19 Wyeth Process for Preparing Indolinone Phenylaminopropanol Derivatives
WO2008071387A1 (en) * 2006-12-11 2008-06-19 Topotarget A/S Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
EP2139856A1 (en) * 2007-04-24 2010-01-06 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
WO2014047437A1 (en) 2012-09-20 2014-03-27 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
US9316631B1 (en) 2012-10-19 2016-04-19 Whitehead Institute For Biomedical Research ER-stress inducing compounds and methods of use thereof
EP2945646A4 (en) * 2013-01-18 2016-09-21 David J Shapiro ESTROGEN RECEPTOR INHIBITORS
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
TN2015000516A1 (en) 2013-05-28 2017-04-06 Astrazeneca Ab Chemical compounds
US20210276951A1 (en) 2018-07-03 2021-09-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response

Also Published As

Publication number Publication date
JP2021529757A (ja) 2021-11-04
SG11202012902WA (en) 2021-01-28
CO2020016690A2 (es) 2021-01-18
CN112423743A (zh) 2021-02-26
EA202190146A1 (ru) 2021-04-27
WO2020009958A1 (en) 2020-01-09
US20200190029A1 (en) 2020-06-18
MA53105A (fr) 2021-05-12
ECSP20084330A (es) 2021-01-29
US11046647B2 (en) 2021-06-29
AU2019299221A1 (en) 2021-02-04
US20210276951A1 (en) 2021-09-09
EP3817741A1 (en) 2021-05-12
US20210340100A1 (en) 2021-11-04
DOP2020000256A (es) 2021-03-15
US11584718B2 (en) 2023-02-21
MX2021000043A (es) 2021-03-25
PH12020552223A1 (en) 2021-06-28
BR112020025591A2 (pt) 2021-03-23
IL279429A (en) 2021-01-31
JOP20200344A1 (ar) 2020-12-31
EP3817741A4 (en) 2022-07-06
CL2020003423A1 (es) 2021-05-14
KR20210027382A (ko) 2021-03-10
CA3103958A1 (en) 2020-01-09
PE20210662A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
CR20210060A (es) Activadores de la respuesta a proteínas desplegadas
MX2020011747A (es) Terapias genicas para los trastornos lisosomales.
CL2018002683A1 (es) Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2020011748A (es) Terapias genicas para los trastornos lisosomales.
AR110728A1 (es) Terapia combinada para el tratamiento del cáncer
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
PH12020551716A1 (en) Anti-ror antibody constructs
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
MX2021000392A (es) Anticuerpos anti-mesotelina.
SA518400027B1 (ar) TNF- a أجسام مضادة لـ وشظايا وظيفية منها
MX2019014049A (es) Metodos de fabricacion y uso de inhibidores de pde9.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
MX2023004480A (es) Compuestos anticancerigenos selectivos para canceres er-positivos.
MX2020012788A (es) Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso.